ClinicalTrials.gg
TerminatedNCT07083349Updated Sep 30, 2026

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

An Early Phase 1 interventional study of NK510 : allogeneic genetic modified NK in Refractory Systemic Lupus Erythematosus, sponsored by Base Therapeutics (Shanghai) Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Base Therapeutics (Shanghai) Co., Ltd. · Early Phase 1, Interventional, and Treatment

Why this study was terminated
poor accrual
Updated Sep 30, 2026Now TerminatedFirst site in China+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
238th of 245
4 · median 36
Started
2025
with 61 others
Phase 1
109 of 266
85 open now
Registered
184th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 238th largest by enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 109 in phase 1, and was the 184th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China.

03

Conditions studied

  • Refractory Systemic Lupus Erythematosus

Keywords

  • SLE
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years old, male or female.
  • A diagnosis of SLE according to the 2019 EULAR (European League Against Rheumatism)/ACR (American College of Rheumatology).
  • The subject voluntarily participates in this clinical study and signs the Form (ICF).
  • Before screening, the subject must have received combined with and/or biological agents for at least 2 months, with a stable dose for more than 2 weeks, but the disease remains active; within 7 days before lymphodepleting conditioning, the blood routine test must meet the following requirements: (ANC) ≥ 1.5×10⁹/L; (Hb) ≥ 80g/L; count (PLT) ≥ 50×10⁹/L.
  • SLEDAI-2K score > 8 points at screening.
  • Antinuclear antibody (ANA) ≥ 1:80 at screening.
  • Having appropriate organ functions:

    1. Liver function: (AST) ≤ 3 times the (ULN); alanine transaminase (ALT) ≤ 3 times ULN; total ≤ 1.5 times ULN, unless the subject has a record of Gilbert syndrome; subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN can be included;
    2. Renal function: serum creatinine ≤ 1.5 times ULN, or rate ≥ 60 mL/min;
    3. Blood routine: absolute neutrophil count (ANC) ≥ 1.5×10⁹/L; absolute lymphocyte count (ALC) ≥ 0.1×10⁹/L; hemoglobin (Hb) ≥ 80 g/L; platelet count (PLT) ≥ 50×10⁹/L.
  • Women of childbearing age must be non-lactating and have a negative serum pregnancy test within 1 week before administration. In addition, all subjects (whether male or female) must agree to use during the period of NK510 treatment starting from enrollment and within 3 months after the end of treatment.
  • Able to comply with the study protocol and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with active lupus nephritis.
  • Those with allergies to the study drug or other medications used in the study protocol.
  • Those with any of the following conditions: ① Having received /allogeneic hematopoietic stem cell transplantation within 3 months; ② Having received ultraviolet irradiation therapy within 6 weeks; ③ Having received biologic agent therapy (excluding other medications used in the study protocol) within 4 weeks or 3 half-lives (whichever is longer); ④ Having undergone major surgery or received within 4 weeks; ⑤ Having received experimental treatment (except for definite placebo control groups) within 4 weeks.
  • Those with other active, known, or suspected diseases.
  • Presence of uncontrolled active bacterial, viral, fungal, mycobacterial, or other infections requiring treatment with intravenous antibiotics, antiviral drugs, or antifungal drugs within 14 days before lymphodepleting conditioning; however, prophylactic use of these drugs (including intravenous administration) is allowed.
  • History of immunodeficiency, including positive test results, or other acquired/congenital immunodeficiency diseases, or history of organ transplantation.
  • History of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac rhythm or conduction abnormalities (e.g., ventricular arrhythmias requiring clinical intervention, third-degree atrioventricular block, etc.); > 480 ms on 12-lead at rest; acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events within 6 months before administration; (NYHA) cardiac function class ≥ II or (LVEF) \< 50%.
  • Failure to fully recover from major surgery or trauma within 2 weeks before administration.
  • History of malignant tumors.
  • Screening results of or C virological tests meeting any of the following:

    1. HBsAg positive, and peripheral blood HBV-DNA titer ≥ 1×10³ copies/mL or ;
    2. Anti- positive.
  • Those deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    NK510 infusion

    NK510

    Drug: NK510 : allogeneic genetic modified NK

Interventions

  • NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10\^7 NK/kg, 8x10\^7 NK/kg and 1.2x10\^8 NK/kg by a dose-escalation design and administered IV.

06

What researchers measure

Primary outcomes

  1. Response rate for SLE response index 4 (SRI4)

    SRI4 response defined as a reduction of ≥4 points on SLEDAI-2000, no new domain A scores and no more than 1 new domain B score on BILAG 2004, and no deterioration in PGA (\<0.3 point increase).

    Time frame: 3 months, 6 months after the first administration of NK510

  2. Incidence of treatment-related adverse events

    This is to measure safety and tolerability of NK510

    Time frame: 1 year

  3. Dose-limiting toxicity (DLT) rate

    This is to measure the dose-limiting toxicity of NK510

    Time frame: 28 days after initial study treatment.

Secondary outcomes

  1. Number of subjects who achieved lupus low disease activity state (LLDAS)

    Low lupus disease activity was defined as SLEDAI-2K ≤ 4 points; no major organ system activity, no active hemolytic anemia or gastrointestinal involvement, and no new disease activity manifestations compared with the previous disease assessment; PGA score ≤ 1 point, daily prednisone equivalent dose ≤ 7.5 mg/day, with the permission of using maintenance doses of antimalarials and immunosuppressants (including biological agents).

    Time frame: 3 months, 6 months after the first administration of NK510

  2. Number of participants who achieved clinical remission of SLE

    Clinical remission of SLE was defined by DORIS SLE remission criteria.

    Time frame: 3 months, 6 months after the first administration of NK510

  3. The change of SLEDAI-2000(Systemic lupus erythematosus disease activity index 2000) scores

    The change of SLEDAI-2000 score (from 0 to 105 points) will be compared to baseline.

    Time frame: Day 28, 3 months, 6 months after the first administration of NK510

  4. Changes of autoantibody of SLE from baseline

    Autoantibody include anti-dsDNA, anti-nuclear antibody, ANA, anti-Sm antibody, and complement C3, C4.

    Time frame: Day 14, 3 months, 6 months after the first administration of NK510

07

Study locations

1 site
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2025 to primary completion in Apr 2026, 4 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Aug 2025 → Dec 2025, primary completion Sep 2027 → Apr 2026 and completion Sep 2027 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Dec 1, 2025was Aug 2025
Primary completionActual
Apr 1, 2026was Sep 2027
CompletionActual
Apr 1, 2026was Sep 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated poor accrual
changed Sep 30, 2026
Sites
1 site added — first site in China
Show site
  • The First Affiliated Hospital of Anhui Medical University · Hefei, China
Sep 30, 2026
Start date
Aug 1, 2025→Dec 1, 2025 (actual)
Sep 30, 2026
Primary completion
Sep 1, 2027→Apr 1, 2026 (actual)
Sep 30, 2026
Study completion
Sep 1, 2027→Apr 1, 2026 (actual)
Sep 30, 2026
Enrollment
9 (estimated)→4 (actual)
Sep 30, 2026
Design
Not applicable→Early Phase 1
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Terminated
    Why stopped poor accrual
    1 site added — first site in China
    Show site
    • The First Affiliated Hospital of Anhui Medical University · Hefei, China
    Start date Aug 1, 2025→Dec 1, 2025 (now actual)
    Primary completion Sep 1, 2027→Apr 1, 2026 (now actual)
    Study completion Sep 1, 2027→Apr 1, 2026 (now actual)
    Enrollment 9 (estimated)→4 (actual)
    Design Not applicable→Early Phase 1
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07083349
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Collaborators
The First Affiliated Hospital of Anhui Medical University
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Dec 1, 2025
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Base Edited Natural Killer Cells NK510

Start the discussion